<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Haematol</journal-id><journal-id journal-id-type="publisher-id">bjh</journal-id><journal-title-group><journal-title>British Journal of Haematology</journal-title></journal-title-group><issn pub-type="ppub">0007-1048</issn><issn pub-type="epub">1365-2141</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19758122</article-id><article-id pub-id-type="pmc">2774145</article-id><article-id pub-id-type="doi">10.1111/j.1365-2141.2009.07814.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib <italic>in vitro</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Amrein</surname><given-names>Lilian</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Panasci</surname><given-names>Lawrence</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gibson</surname><given-names>Spencer B</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>James B</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Souli&#x000e8;res</surname><given-names>Denis</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Aloyz</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><aff id="au1"><label>1</label><institution>Lady Davis Institute for Medical Research-Cancer Segal Center, Sir M.B. Davis-Jewish General Hospital</institution><addr-line>Montreal, QC</addr-line></aff><aff id="au2"><label>2</label><institution>Montreal Center for Experimental Therapeutics, McGill University</institution><addr-line>Montreal, QC</addr-line></aff><aff id="au3"><label>3</label><institution>Manitoba Institute of Cell Biology, Cancer Care Manitoba</institution><addr-line>Winnipeg, MB</addr-line></aff><aff id="au4"><label>4</label><institution>Department of Medicine, Service of Hematology and Medical Oncology, Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al and Centre de Recherche du CHUM</institution><addr-line>Sherbrooke East, Montreal, QC, Canada</addr-line> E-mail: <email>raloyz@yahoo.com</email></aff></contrib-group><pub-date pub-type="ppub"><month>11</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>02</day><month>9</month><year>2009</year></pub-date><volume>147</volume><issue>3</issue><fpage>396</fpage><lpage>410</lpage><permissions><copyright-statement>&#x000a9; 2009 Blackwell Publishing Ltd</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions></article-meta></front><body><p>Chronic lymphocytic leukaemia (CLL) is characterized by the accumulation of mature quiescent B-lymphocytes in the G0/G1 phase of the cell cycle. B-lymphocyte accumulation is likely to be a consequence of an undefined defect in the apoptotic machinery rather than an increased proliferation of leukaemic cells (<xref ref-type="bibr" rid="b5">Hamblin &#x00026; Oscier, 1997</xref>). The prolonged survival of CLL lymphocytes has also been linked to deregulated expression and/or activity of related non receptor tyrosine kinases including members of the <italic>SRC</italic> family kinases (SFK) and <italic>ABL1</italic>. Inhibition of either c-abl (<xref ref-type="bibr" rid="b1">Aloyz <italic>et al</italic>, 2004</xref>) or SFK (<xref ref-type="bibr" rid="b4">Contri <italic>et al</italic>, 2005</xref>) results in CLL lymphocyte death <italic>in vitro</italic>. Previous results from our laboratory suggest that dasatinib cytotoxicity in CLL lymphocytes is associated with c-abl rather than SFK inhibition (<xref ref-type="bibr" rid="b2">Amrein <italic>et al</italic>, 2008a</xref>). Recent results of phase I&#x02013;II clinical trials using dasatinib in CLL suggest that the drug might be beneficial in only a small subset (&#x02264;10%) of previously treated patients (<xref ref-type="bibr" rid="b3">Amrein <italic>et al</italic>, 2008b</xref>). In agreement with these clinical results, we have recently reported that dasatinib is cytotoxic to primary CLL lymphocytes <italic>in vitro</italic> but mainly at clinically unobtainable concentrations (<xref ref-type="bibr" rid="b2">Amrein <italic>et al</italic>, 2008a</xref>). Although dasatinib resistance was associated with the basal expression of c-abl, our study suggested that wild type <italic>TP53</italic> is important in CLL lymphocyte homeostasis and/or survival in the presence of dasatinib (<xref ref-type="bibr" rid="b2">Amrein <italic>et al</italic>, 2008a</xref>). To test this hypothesis we assessed: (i) dasatinib cytotoxicity in p53 proficient (wild type) CLL lymphocytes treated with dasatinib in the presence or absence of pifithrin<italic>-</italic>&#x003b1;, a small molecule inhibitor of p53 transcriptional activity (<xref ref-type="bibr" rid="b8">Steele <italic>et al</italic>, 2008</xref>) and 2) dasatinib cytotoxicity in primary CLL lymphocytes with impaired <italic>TP53</italic> signalling from patients diagnosed with del 17p13.1. In the eleven samples we verified the functionality of p53 signalling as described before by examining changes in p53 and its downstream target p21Cip1 (p21) after treatment with chlorambucil (<xref ref-type="bibr" rid="b9">Willmore <italic>et al</italic>, 2008</xref>). Briefly, the lymphocytes were treated with equivalent cytotoxic concentrations of chlorambucil (50% inhibitory concentrations [IC<sub>50</sub>&#x02019;s]) for 24 h and induced p53 and p21 protein levels were monitored by Western blotting. As expected p53 and p21 protein levels were induced by chlorambucil only in <italic>TP53</italic> wild type CLL lymphocytes (data not shown).</p><p>As previously reported, dasatinib IC<sub>50</sub>s <italic>in vitro</italic> in CLL lymphocytes expressing wild type <italic>TP53</italic> were not in the clinically attainable range (mean value of 30 &#x003bc;mol/l, <xref ref-type="table" rid="tbl1">Table I</xref>) (<xref ref-type="bibr" rid="b2">Amrein <italic>et al</italic>, 2008a</xref>). In contrast, the dasatinib IC<sub>50</sub>s in del 17p13.1 lymphocytes were significantly lower (up to 100 times) than in the wild type <italic>TP53</italic> lymphocytes. Moreover, in agreement with previous reports demonstrating that del 17p13.1 is associated with chemoresistance in CLL lymphocytes, we found that del 17p13.1 lymphocytes were significantly more resistant to chlorambucil that <italic>TP53</italic> wild type CLL lymphocytes [<xref ref-type="table" rid="tbl1">Table I</xref>, <xref ref-type="fig" rid="fig01">Fig 1A</xref> (<xref ref-type="bibr" rid="b10">Zenz <italic>et al</italic>, 2008</xref>)].</p><table-wrap id="tbl1" position="float"><label>Table I</label><caption><p>Clinical characteristic of the patients and IC<sub>50</sub> concentrations of dasatinib and chlorambucil in primary CLL-lymphocytes <italic>in vitro</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">Deletion 17 Deletion 11</th><th align="center" rowspan="1" colspan="1">RAI stage</th><th align="center" rowspan="1" colspan="1">Previous treatment</th><th align="center" rowspan="1" colspan="1">Dasatinib (&#x003bc;mol/l)</th><th align="center" rowspan="1" colspan="1">CLB (&#x003bc;mol/l)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">CLB</td><td align="center" rowspan="1" colspan="1">0&#x000b7;8</td><td align="center" rowspan="1" colspan="1">17&#x000b7;3</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">FLU</td><td align="center" rowspan="1" colspan="1">30&#x000b7;6 (2&#x000b7;4)</td><td align="center" rowspan="1" colspan="1">23&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">CLB</td><td align="center" rowspan="1" colspan="1">7&#x000b7;2</td><td align="center" rowspan="1" colspan="1">30&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">0&#x000b7;1</td><td align="center" rowspan="1" colspan="1">41&#x000b7;0</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">36&#x000b7;0 (27&#x000b7;0)</td><td align="center" rowspan="1" colspan="1">18&#x000b7;6</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">CLB</td><td align="center" rowspan="1" colspan="1">28&#x000b7;2</td><td align="center" rowspan="1" colspan="1">10&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">CLB</td><td align="center" rowspan="1" colspan="1">40&#x000b7;0 (40&#x000b7;0)</td><td align="center" rowspan="1" colspan="1">24&#x000b7;9</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Del 17p13.1 (86%) Del 11q22&#x02013;23 (N.D.)</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">CLB</td><td align="center" rowspan="1" colspan="1">0&#x000b7;27</td><td align="center" rowspan="1" colspan="1">36&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Del 17p13.1 (94%) Del 11q22&#x02013;23 (5%)</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">CLB/FLU/Rituximab</td><td align="center" rowspan="1" colspan="1">0&#x000b7;01</td><td align="center" rowspan="1" colspan="1">44&#x000b7;7</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Del 17p13.1 (79%) Del 1q22&#x02013;231 (76%)</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">0&#x000b7;01</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">Del 17p13.1 (33%) Del 11q22&#x02013;23 (10%)</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">CLB</td><td align="center" rowspan="1" colspan="1">0&#x000b7;17</td><td align="center" rowspan="1" colspan="1">100</td></tr></tbody></table><table-wrap-foot><fn><p>Primary CLL lymphocytes, isolated and plated as described above, were incubated in the presence of dasatinib or chlorambucil (CLB). The IC<sub>50</sub> concentrations are expressed in &#x003bc;mol/l and determined after 72 h incubation <italic>in vitro</italic> using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay as described (<xref ref-type="bibr" rid="b2">Amrein <italic>et al</italic>, 2008a</xref>). The numbers in parentheses indicate the dasatinib IC<sub>50</sub> in the presence of 25 &#x003bc;mol/l pifithrin-&#x003b1;. The percentage of lymphocytes with del 17 and del 11 in each samples are indicated. Samples displaying percentages above 4&#x000b7;8% and 6&#x000b7;6% for del 17 and del 11 respectively were considered positive.</p></fn><fn><p>Negative percentage lower than the cut-off point.</p></fn><fn><p>N.D. not determined; CLB, chlorambucil.</p></fn></table-wrap-foot></table-wrap><fig id="fig01" position="float"><label>Fig 1</label><caption><p>Dasatinib decreases p53 basal expression levels in primary CLL lymphocytes expressing wild type p53. Dasatinib and chlorambucil IC<sub>50</sub>s were significantly different between CLL lymphocytes expressing wild type <italic>TP53</italic> or del 17 (*<italic>P</italic> = 0.012). The bars represent the median values and 95% confidence intervals (CI 95%). (A). The lymphocytes of 11 CLL lymphocyte patients were treated for 24 h with vehicle (dimethyl sulphoxide), dasatinib 100 nmol/l or the IC<sub>50</sub> concentration as shown in <xref ref-type="table" rid="tbl1">Table I</xref>. Protein extracts were obtained as described before and 50 &#x003bc;g of proteins for each sample were resolved by sodium dodecyl sulphate poyacrylamide gel electrophoresis. p53 and p21 protein levels were assessed by Western blot using specific antibodies (<xref ref-type="bibr" rid="b2">Amrein <italic>et al</italic>, 2008a</xref>). The signals obtained in <italic>TP53</italic> wild type lymphocytes (B) were analysed using National Institutes of Health -Scion image and normalized to actin, p53 or p21 levels (<italic>y</italic>-axis) and are expressed as the percentage of vehicle treated lymphocytes (control) value ([OD value/control OD value]x 100) vis &#x000e0; vis the treatments indicated in the <italic>x</italic>-axis; * and ** indicates significance <italic>P</italic> = 0&#x000b7;003 and <italic>P</italic> = 0&#x000b7;004 respectively (C). Dasatinib-induced changes in p53 levels and p21 signal were not detected in protein extracts from del 17p13&#x000b7;1 CLL lymphocytes (D). Dasatinib IC<sub>50</sub>s correlate with the percentage of residual p53 protein levels (in respect to vehicle treated lymphocytes) after dasatinib treatment, <italic>r</italic> = 0&#x000b7;82, <italic>P</italic> = 0&#x000b7;02 (E). Two-sided tests with &#x003b1;-value of 0&#x000b7;05 were used. Correlations between the data were assessed using the Spearman test. All tests were performed using SigmaStat software.</p></caption><graphic xlink:href="bjh0147-0396-f1"/></fig><p>In available wild type <italic>TP53</italic> CLL samples, pifithrin<italic>-&#x003b1;</italic> sensitized the lymphocytes of 2 out 3 patients (1&#x000b7;3 and 12-fold) (<xref ref-type="table" rid="tbl1">Table I</xref>). Importantly, pifithrin-<italic>&#x003b1;</italic> was not toxic to CLL lymphocytes when used alone. Treatment with dasatinib for twenty four hours resulted in a dose dependent reduction of p53 and p21 basal expression levels in the lymphocytes of patients expressing wild type <italic>TP53</italic> (<xref ref-type="fig" rid="fig01">Fig 1B, C</xref>). In contrast, p53 levels were not affected in del 17 lymphocytes. Importantly, p21 was not detected in del 17p13.1 lymphocytes suggesting that <italic>TP53</italic> is not functional (<xref ref-type="fig" rid="fig01">Fig 1D</xref>). These results are in agreement with previous reports suggesting that in the majority of CLL patients with malignant lymphocytes displaying del 17p13.1, the remaining <italic>TP53</italic> allele is mutated (<xref ref-type="bibr" rid="b10">Zenz <italic>et al</italic>, 2008</xref>).</p><p>In addition, we found that dasatinib resistance (higher IC<sub>50</sub>) in CLL lymphocytes expressing wild type <italic>TP53</italic> correlated with residual p53 protein levels (in respect to control) after dasatinib treatment (<italic>r</italic> = 0&#x000b7;8, <italic>P</italic> = 0&#x000b7;02, <xref ref-type="fig" rid="fig01">Fig 1E</xref>). As <italic>ATM</italic> is a key regulator of p53 functionality, we assessed del 11q22-23 status in del 17p13.1 lymphocytes (<xref ref-type="table" rid="tbl1">Table I</xref>) (<xref ref-type="bibr" rid="b6">Pettitt <italic>et al</italic>, 2001</xref>). Two of the three del 17p13.1 samples tested were positive for del 11q22&#x02013;23. Although del 17p13.1 lymphocytes were hypersensitive when compared to p53 proficient lymphocytes, we did not find a correlation between the percentage of del 17p13.1 or del 11q22&#x02013;23 in the lymphocytes and the IC<sub>50</sub> of dasatinib. Studies regarding the role of p53 signalling (and its regulators e.g. ATM) in dasatinib sensitivity in a larger cohort of CLL samples should be informative.</p><p>Taken together, our results suggest that p53 is important to maintain CLL lymphocyte homeostasis following exposure to dasatinib and suggest that dasatinib may be effective to treat del 17p13.1 CLL patients. The recent report of an excellent clinical response to dasatinib of a CLL patient with lymphocytes displaying del 17p13.1 supports this hypothesis (<xref ref-type="bibr" rid="b7">Pitini <italic>et al</italic>, 2009</xref>).</p></body><back><ack><p>This work was supported by a CIHR grant to R. Aloyz.</p></ack><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aloyz</surname><given-names>R</given-names></name><name><surname>Grzywacz</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>ZY</given-names></name><name><surname>Loignon</surname><given-names>M</given-names></name><name><surname>Alaoui-Jamali</surname><given-names>MA</given-names></name><name><surname>Panasci</surname><given-names>L</given-names></name></person-group><article-title>Imatinib sensitizes CLL lymphocytes to chlorambucil</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">14712290</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amrein</surname><given-names>L</given-names></name><name><surname>Hernandez</surname><given-names>TA</given-names></name><name><surname>Ferrario</surname><given-names>C</given-names></name><name><surname>Johnston</surname><given-names>J</given-names></name><name><surname>Gibson</surname><given-names>SB</given-names></name><name><surname>Panasci</surname><given-names>L</given-names></name><name><surname>Aloyz</surname><given-names>R</given-names></name></person-group><article-title>Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro</article-title><source>British Journal of Haematology</source><year>2008a</year><volume>143</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">19062342</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amrein</surname><given-names>PC</given-names></name><name><surname>Attar</surname><given-names>E</given-names></name><name><surname>Takvorian</surname><given-names>T</given-names></name><name><surname>Hochberg</surname><given-names>E</given-names></name><name><surname>Ballen</surname><given-names>KK</given-names></name><name><surname>Leahy</surname><given-names>KM</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name></person-group><article-title>Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial</article-title><source>Blood</source><year>2008b</year><volume>112</volume><fpage>1084</fpage></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contri</surname><given-names>A</given-names></name><name><surname>Brunati</surname><given-names>AM</given-names></name><name><surname>Trentin</surname><given-names>L</given-names></name><name><surname>Cabrelle</surname><given-names>A</given-names></name><name><surname>Miorin</surname><given-names>M</given-names></name><name><surname>Cesaro</surname><given-names>L</given-names></name><name><surname>Pinna</surname><given-names>LA</given-names></name><name><surname>Zambello</surname><given-names>R</given-names></name><name><surname>Semenzato</surname><given-names>G</given-names></name><name><surname>Donella-Deana</surname><given-names>A</given-names></name></person-group><article-title>Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis</article-title><source>Journal of Clinical Investigation</source><year>2005</year><volume>115</volume><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">15650771</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamblin</surname><given-names>TJ</given-names></name><name><surname>Oscier</surname><given-names>DG</given-names></name></person-group><article-title>Chronic lymphocytic leukaemia: the nature of the leukaemic cell</article-title><source>Blood Reviews</source><year>1997</year><volume>11</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">9370043</pub-id></element-citation></ref><ref id="b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettitt</surname><given-names>AR</given-names></name><name><surname>Sherrington</surname><given-names>PD</given-names></name><name><surname>Stewart</surname><given-names>G</given-names></name><name><surname>Cawley</surname><given-names>JC</given-names></name><name><surname>Taylor</surname><given-names>AMR</given-names></name><name><surname>Stankovic</surname><given-names>T</given-names></name></person-group><article-title>p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>814</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">11468183</pub-id></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitini</surname><given-names>V</given-names></name><name><surname>Arrigo</surname><given-names>C</given-names></name><name><surname>Altavilla</surname><given-names>G</given-names></name></person-group><article-title>Dasatinib induces a response in chronic lymphocytic leukemia</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>498</fpage><pub-id pub-id-type="pmid">19131559</pub-id></element-citation></ref><ref id="b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>AJ</given-names></name><name><surname>Prentice</surname><given-names>AG</given-names></name><name><surname>Hoffbrand</surname><given-names>AV</given-names></name><name><surname>Yogashangary</surname><given-names>BC</given-names></name><name><surname>Hart</surname><given-names>SM</given-names></name><name><surname>Nacheva</surname><given-names>EP</given-names></name><name><surname>Howard-Reeves</surname><given-names>JD</given-names></name><name><surname>Duke</surname><given-names>VM</given-names></name><name><surname>Kottaridis</surname><given-names>PD</given-names></name><name><surname>Cwynarski</surname><given-names>K</given-names></name><name><surname>Vassilev</surname><given-names>LT</given-names></name><name><surname>Wickremasinghe</surname><given-names>RG</given-names></name></person-group><article-title>p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism</article-title><source>Blood</source><year>2008</year><volume>112</volume><fpage>3827</fpage><lpage>3834</lpage><pub-id pub-id-type="pmid">18682598</pub-id></element-citation></ref><ref id="b9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willmore</surname><given-names>E</given-names></name><name><surname>Elliott</surname><given-names>SL</given-names></name><name><surname>Mainou-Fowler</surname><given-names>T</given-names></name><name><surname>Summerfield</surname><given-names>GP</given-names></name><name><surname>Jackson</surname><given-names>GH</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>F</given-names></name><name><surname>Lowe</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Pettitt</surname><given-names>AR</given-names></name><name><surname>Cano-Soumillac</surname><given-names>C</given-names></name><name><surname>Griffin</surname><given-names>RJ</given-names></name><name><surname>Cowell</surname><given-names>IG</given-names></name><name><surname>Austin</surname><given-names>CA</given-names></name><name><surname>Durkacz</surname><given-names>BW</given-names></name></person-group><article-title>DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia</article-title><source>Clinical Cancer Research</source><year>2008</year><volume>14</volume><fpage>3984</fpage><lpage>3992</lpage><pub-id pub-id-type="pmid">18559621</pub-id></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenz</surname><given-names>T</given-names></name><name><surname>Benner</surname><given-names>A</given-names></name><name><surname>Dohner</surname><given-names>H</given-names></name><name><surname>Stilgenbauer</surname><given-names>S</given-names></name></person-group><article-title>Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><fpage>3810</fpage><lpage>3814</lpage><pub-id pub-id-type="pmid">19098429</pub-id></element-citation></ref></ref-list></back></article>